BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens in AstraZeneca’s early Vaccines & Immune Therapies pipeline.

波士顿和圣路易斯--（商业新闻短讯）--临床前生物技术公司Omniose今天宣布与阿斯利康达成独家合作协议，在阿斯利康的早期疫苗和免疫疗法管道中研究潜在的细菌病原体疫苗。

Under the terms of the agreement, AstraZeneca will have exclusive rights to Omniose’s proprietary bioconjugation platform for up to three years, which allows for the development of high-quality vaccines against a range of bacterial pathogens, including multidrug-resistant “superbugs” previously intractable by other methods..

根据协议条款，阿斯利康将拥有Omniose专有生物缀合平台长达三年的专有权，该平台允许开发针对一系列细菌病原体的高质量疫苗，包括以前难以通过其他方法治疗的耐多药“超级细菌”。。

Conjugate vaccines are an effective form of immunization however, their use is limited due to the complex chemical process of attaching bacterial polysaccharides to engineered carrier proteins. Bioconjugation greatly streamlines the manufacturing process compared to chemical conjugation and may produce a higher quality vaccine..

结合疫苗是一种有效的免疫形式，然而，由于将细菌多糖附着到工程载体蛋白上的复杂化学过程，它们的使用受到限制。与化学缀合相比，生物缀合大大简化了制造过程，并可能产生更高质量的疫苗。。

Christian Harding, CSO & Co-founder of Omniose, added: “Our synthetic biology platform is the broadest enzyme-based bioconjugation system enabling the transfer of virtually any bacterial polysaccharide to engineered carrier proteins.”

CSO兼Omniose联合创始人克里斯蒂安·哈丁（ChristianHarding）补充道：“我们的合成生物学平台是最广泛的基于酶的生物缀合系统，可以将几乎任何细菌多糖转移到工程载体蛋白中。”

Mark Esser, Vice President, Early R&D Vaccines & Immune Therapies AstraZeneca, commented: “As serious bacterial infections become increasingly resistant to commonly-used antibiotics, the development of alternative preventative interventions is critical. As part of our ambition to provide long-lasting immunity to millions of people, we are excited to enter into this scientific collaboration with Omniose to explore the role of this novel bioconjugate platform in developing vaccines for bacterial pathogens.”.

Mark Esser，阿斯利康早期研发疫苗和免疫疗法副总裁，评论：“随着严重的细菌感染对常用抗生素的耐药性越来越强，开发替代性预防干预措施至关重要。作为我们为数百万人提供持久免疫力的雄心壮志的一部分，我们很高兴与Omniose进行这项科学合作，以探索这种新型生物共轭平台在开发疫苗中的作用细菌病原体”。

Timothy Cooke, CEO of Omniose said: “AstraZeneca has deep expertise in leveraging next-generation technology to advance infectious disease research and we are proud to collaborate with them to realize the full potential of our conjugate vaccine platform.”

Omniose首席执行官蒂莫西·库克（TimothyCooke）表示：“阿斯利康在利用下一代技术推进传染病研究方面拥有丰富的专业知识，我们很荣幸与他们合作，充分发挥我们结合疫苗平台的潜力。”

About Omniose

关于Omniose

The Omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell. Bioconjugation is a much simpler process than conventional chemical conjugation methods and has the potential to produce higher quality vaccines as it retains the natural polysaccharide structure elaborated by a bacterial pathogen.

Omniose生物缀合疫苗平台能够将几乎任何细菌多糖抗原精确地酶促附着到单个大肠杆菌细胞内的工程载体蛋白上。生物缀合比传统的化学缀合方法简单得多，并且具有生产更高质量疫苗的潜力，因为它保留了由细菌病原体阐述的天然多糖结构。

Previous enzymes used for bioconjugation thus far could only address a limited range of bacterial targets. Omniose is breaking through this barrier by expanding the scope of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation..

迄今为止，用于生物缀合的先前酶只能解决有限范围的细菌靶标。Omniose正在通过扩大可以开发的细菌疫苗的范围来突破这一障碍，同时利用生物缀合已经确立的益处。。